Answers are grounded in this paper and cite their sources.
RhoH is an atypical Rho GTPase that primarily regulates immunological functions in T-cells. Dysregulation of RhoH has been implicated in various diseases, particularly hematological cancers such as lymphoma and leukemia. However, recent studies have also identified aberrant RhoH expression in non-hematological conditions, including systemic lupus erythematosus (SLE), chronic psoriasis, and epithelial cancer cell lines, despite RhoH being predominantly expressed in hematopoietic cells. Despite these findings, there has been limited systematic review of RhoH dysregulation across different human diseases. To address this gap, this systematic literature review (SLR) investigates the characteristics of RhoH dysregulation in both cancerous and non-cancerous human diseases, regardless of their hematological nature. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we conducted a thorough search of three major scientific databases: PubMed, Scopus and Web of Science, to identify relevant articles for analysis. The review focuses on two key themes: (1) the types of human diseases associated with RhoH dysregulation and (2) the specific characteristics of RhoH dysregulation. This comprehensive review enhances our understanding of the diverse diseases linked to RhoH dysregulation, providing a foundation for future research into its underlying mechanisms in signalling and disease pathogenesis.
No takes yet. Share an insight, caveat, or question.
Saw et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: